Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharon Spencer

Showing results (21-30 of 45) with videos related to

Pageof 5
Sort By:
Human Pathology|December 21, 2013
African Americans with oropharyngeal carcinoma have significantly poorer outcomes despite similar rates of human papillomavirus-mediated carcinogenesisTatyana Isayeva, Jie Xu, Qian Dai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 28, 2009
NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancerBarbara Burtness, Milan Anadkat, Surendra Basti, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2016
Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trialJames A Bonner, Jordi Giralt, Paul M Harari, et al.
International Journal of Radiation Oncology, Biology, Physics|August 25, 2010
Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinomaChristine H Chung, Qiang Zhang, Elizabeth M Hammond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2011
Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003)Christine H Chung, James J Dignam, M Elizabeth Hammond, et al.
Head & Neck|August 23, 2019
Changing functional status within 6 months posttreatment is prognostic of overall survival in patients with head and neck cancer: NRG Oncology StudyRonald C Eldridge, Stephanie L Pugh, Andy Trotti, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 26, 2026
Randomized, double-blind, sham-controlled trial of an intraoral photobiomodulation device for oral mucositis and associated complications due to radiotherapy for head and neck cancerKenneth Hu, Pratish Shah, M Connie Nguyen, et al.
International Journal of Radiation Oncology, Biology, Physics|April 3, 2020
Location as Destiny: Identifying Geospatial Disparities in Radiation Treatment Interruption by Neighborhood, Race, and InsuranceDaniel V Wakefield, Matthew Carnell, Austin P H Dove, et al.
Practical Radiation Oncology|July 30, 2024
Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice GuidelineDanielle N Margalit, Christopher J Anker, Michalis Aristophanous, et al.
Cancer|March 27, 2019
Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trialsCarole Fakhry, Qiang Zhang, Maura L Gillison, et al.
Pageof 5

Showing results (21-30 of 45) with videos related to

Sort By:
Pageof 5
Human Pathology|December 21, 2013
African Americans with oropharyngeal carcinoma have significantly poorer outcomes despite similar rates of human papillomavirus-mediated carcinogenesisTatyana Isayeva, Jie Xu, Qian Dai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 28, 2009
NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancerBarbara Burtness, Milan Anadkat, Surendra Basti, et al.
European Journal of Cancer (Oxford, England : 1990)|June 21, 2016
Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trialJames A Bonner, Jordi Giralt, Paul M Harari, et al.
International Journal of Radiation Oncology, Biology, Physics|August 25, 2010
Integrating epidermal growth factor receptor assay with clinical parameters improves risk classification for relapse and survival in head-and-neck squamous cell carcinomaChristine H Chung, Qiang Zhang, Elizabeth M Hammond, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2011
Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003)Christine H Chung, James J Dignam, M Elizabeth Hammond, et al.
Head & Neck|August 23, 2019
Changing functional status within 6 months posttreatment is prognostic of overall survival in patients with head and neck cancer: NRG Oncology StudyRonald C Eldridge, Stephanie L Pugh, Andy Trotti, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|June 26, 2026
Randomized, double-blind, sham-controlled trial of an intraoral photobiomodulation device for oral mucositis and associated complications due to radiotherapy for head and neck cancerKenneth Hu, Pratish Shah, M Connie Nguyen, et al.
International Journal of Radiation Oncology, Biology, Physics|April 3, 2020
Location as Destiny: Identifying Geospatial Disparities in Radiation Treatment Interruption by Neighborhood, Race, and InsuranceDaniel V Wakefield, Matthew Carnell, Austin P H Dove, et al.
Practical Radiation Oncology|July 30, 2024
Radiation Therapy for HPV-Positive Oropharyngeal Squamous Cell Carcinoma: An ASTRO Clinical Practice GuidelineDanielle N Margalit, Christopher J Anker, Michalis Aristophanous, et al.
Cancer|March 27, 2019
Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: Implications for risk-based therapeutic intensity trialsCarole Fakhry, Qiang Zhang, Maura L Gillison, et al.
Pageof 5